JSPCCS-AHA Joint Session（II-AHAJS）
先天性心疾患における新規心不全治療薬の夜明け/Dawn of new drugs for heart failure in patients with congenital heart disease
第一部「先天性心疾患における新規心不全治療薬の国内使用経験」
第二部「先天性心疾患における新規心不全治療薬の日米使用経験」

[II-AHAJS-10] Future Prospects for Novel Heart Failure Therapeutics in CHD - From the AHA Side

^○Kimberly Y. Lin (Children’s Hospital of Philadelphia and Current chair of the Young Hearts Heart Failure and Transplant Committee, USA)

The development of new drugs for the treatment of heart failure has had a tremendous impact on outcomes for adults. However, such benefit in congenital heart disease from novel medications have have not come to fruition quite so convincingly. During this talk, I will discuss the potential role of novel therapies in CHD. We will specifically explore the potential use of SGLT2 inhibitors, myosin inhibitors, soluble guanylate cyclase (sGC) stimulators, and we will also look at prospects for cell- and gene-based therapies in the future. It will be interesting to compare this North American perspective with that of the Japanese perspective towards our field’s mutual, future prospects.